We are live on ! Find out more
FSTX

F-star Therapeutics, Inc. Common Stock
FSTX

Delisted

FSTX was delisted on the 8th of March, 2023.

Back to rankings

33 hedge funds and large institutions have $48.7M invested in F-star Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 1

375% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 4

364% more capital invested

Capital invested by funds: $10.5M → $48.7M (+$38.3M)

83% more funds holding

Funds holding: 18 → 33 (+15)

Holders
33
Holders Change
+15
Holders Change %
+83.33%
% of All Funds
0.82%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
10
Reduced
1
Closed
4
Calls
$2.71M
Puts
–
Net Calls
+$2.71M
Net Calls Change
+$928K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$7.13M
2
RI
RTW Investments
New York
+$2.89M
3
Alyeska Investment Group
Alyeska Investment Group
Illinois
+$2.84M
4
Axa
Axa
France
+$2.47M
5
SFM
Sphera Funds Management
Israel
+$2.03M

Top Sellers

Rank Fund Capital Flow
1
Charles Schwab
Charles Schwab
California
-$252K
2
Luther King Capital Management (LKCM)
Luther King Capital Management (LKCM)
Texas
-$239K
3
Goldman Sachs
Goldman Sachs
New York
-$180K
4
Millennium Management
Millennium Management
New York
-$174K
5
Bessemer Group
Bessemer Group
New Jersey
-$11K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$8.33M +$7.13M +153,846 New
Alyeska Investment Group
2
Alyeska Investment Group
Illinois
$5.39M +$2.84M +61,380 +161%
BBA
3
Baker Bros. Advisors
New York
$5.05M +$1.78M +38,461 +70%
TA
4
Tiedemann Advisors
New York
$4.9M +$597K +12,889 +17%
PCM
5
Parsons Capital Management
Rhode Island
$3.73M +$490K +10,571 +18%
RI
6
RTW Investments
New York
$3.38M +$2.89M +62,500 New
Axa
7
Axa
France
$2.89M +$2.47M +53,431 New
SFM
8
Sphera Funds Management
Israel
$2.37M +$2.03M +43,750 New
SAM
9
Sectoral Asset Management
Quebec, Canada
$1.52M +$1.3M +28,125 New
MIM
10
Monashee Investment Management
Massachusetts
$1.35M +$1.16M +25,000 New
CM
11
Crestline Management
Texas
$1.33M +$1.14M +24,645 New
HCM
12
Highbridge Capital Management
New York
$1.02M +$868K +18,750 New
SAM
13
Silvercrest Asset Management
New York
$993K +$849K +18,336 New
MAM
14
Morse Asset Management
Connecticut
$862K +$450K +9,725 +157%
Vanguard Group
15
Vanguard Group
Pennsylvania
$794K +$679K +14,651 New
PCA
16
Private Capital Advisors
Connecticut
$762K +$217K +4,688 +50%
Millennium Management
17
Millennium Management
New York
$677K -$174K -3,755 -23%
EI
18
EAM Investors
California
$578K +$494K +10,666 New
Renaissance Technologies
19
Renaissance Technologies
New York
$462K +$395K +8,526 New
CWG
20
C WorldWide Group
Denmark
$340K +$291K +6,281 New
Deutsche Bank
21
Deutsche Bank
Germany
$290K +$247K +5,334 +21,336%
BlackRock
22
BlackRock
New York
$288K +$245K +5,288 +12,898%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$273K +$234K +5,044 New
LF
24
Lee Financial
Texas
$254K – – –
VV
25
Verity & Verity
South Carolina
$241K – – –
1
2

FSTX Hedge Fund Activity: Q2 2017 in Review

33 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q2 2017, worth a combined $48.7M — up 364% from $10.5M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new FSTX positions and 4 closed out — a net gain of 15 holders — while 10 added to existing stakes and 1 trimmed.

The largest buyer was BVF Inc, opening a new position worth an estimated $7.13M. The largest seller was Charles Schwab, exiting entirely with an estimated $252K sold.

  • 33 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q2 2017, up from 18 in Q1 2017.
  • Funds reported $48.7M of F-star Therapeutics, Inc. Common Stock stock for Q2 2017, up 364% quarter-over-quarter.
  • 19 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q2 2017 and 4 closed out, a net change of +15 holders.
  • The largest F-star Therapeutics, Inc. Common Stock buyer in Q2 2017 was BVF Inc, an estimated $7.13M added.
  • The largest F-star Therapeutics, Inc. Common Stock seller in Q2 2017 was Charles Schwab, an estimated $252K sold.

Based on aggregated 13F filings for Q2 2017.